Subscribe
shutterstock_1826152037_lev_radin
Lev Radin / Shutterstock.com
8 March 2021Big PharmaAlex Baldwin

A deep dive into Regeneron v Kymab

On June 24, 2020, a seven-year-long legal battle between two biotech companies finally concluded in the UK.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Alnylam and Regeneron unveil RNAi partnership
9 April 2019   Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Alnylam and Regeneron unveil RNAi partnership
9 April 2019   Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

More on this story

Americas
Alnylam and Regeneron unveil RNAi partnership
9 April 2019   Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.
Generics
Amgen prevails against Sanofi and Regeneron
26 February 2019   A jury has upheld two of Amgen’s patents for its cholesterol drug Repatha, rejecting a challenge brought by two competitors.
Big Pharma
Regeneron asks court to dismiss COVID-19 tech patent suit
24 August 2021   Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York